DEA Adds Obscure Cathinone to Schedule I Controlled List
Published Date: 11/17/2025
Rule
Summary
Starting December 17, 2025, 4-chloromethcathinone (4-CMC) is officially a Schedule I drug, meaning it’s now tightly controlled like other dangerous substances. This change affects anyone who makes, sells, studies, or even just possesses 4-CMC, bringing serious legal rules and penalties. The move helps the U.S. follow international drug laws and keeps communities safer without adding new costs.
Analyzed Economic Effects
5 provisions identified: 0 benefits, 4 costs, 1 mixed.
4‑CMC officially placed in Schedule I
Starting December 17, 2025, 4‑chloromethcathinone (4‑CMC) is permanently listed as a Schedule I controlled substance. This means handling or possessing any amount without proper authorization is unlawful and subject to the civil, administrative, and criminal sanctions that apply to Schedule I drugs.
DEA registration required to handle 4‑CMC
Anyone who manufactures, distributes, reverse distributes, imports, exports, engages in research, conducts instructional activities or chemical analysis with, or possesses 4‑CMC must register with DEA under 21 U.S.C. 822, 823, 957, and 958 and 21 CFR parts 1301 and 1312. Persons who currently handle 4‑CMC but are not registered must apply for registration and may not continue handling 4‑CMC unless DEA approves the registration.
Surrender or transfer stocks before the effective date
If you are unwilling or unable to obtain a Schedule I registration, you must surrender or transfer all quantities of 4‑CMC to a DEA‑registered person before the effective date (December 17, 2025). Any remaining 4‑CMC must be disposed of in accordance with 21 CFR part 1317 and all applicable laws.
Research allowed but requires Schedule I authorization
Placing 4‑CMC in Schedule I does not bar academic or scientific research, but researchers must obtain Schedule I researcher registration to handle the substance. DEA directs prospective researchers to apply through the Schedule I researcher registration program to obtain permission to study 4‑CMC.
Specific compliance duties: inventories, security, records
DEA registrants handling 4‑CMC must follow Schedule I requirements including initial inventory on the date they first handle controlled substances, inventories every two years thereafter, security and employee‑screening rules (21 CFR 1301.71‑1301.76 and 1301.90‑1301.93), labeling/packaging rules, quotas for manufacture, order form rules, and recordkeeping and reporting requirements under 21 CFR parts 1301, 1302, 1303, 1304, 1312, and 1317.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-20000, Renaming of Restricted Areas R-6302A, R-6302B, R-6302C, R-6302D, and R-6302E; Fort Cavazos, TX
The FAA is updating the names of restricted airspace areas R-6302A through R-6302E to reflect the Army’s renaming of Fort Hood, TX, to Fort Cavazos, TX. This change won’t affect airspace boundaries or how pilots use the space. The new names take effect on January 22, 2026, with no costs or new rules for anyone flying nearby.
Next: 2025-20007, Technical Amendment to List of User Fee Airports: Addition of Five Airports, Removal of One Airport
Starting November 17, 2025, five airports in Colorado, California, Florida, and Oregon are joining the list where international flights pay user fees, while one airport in California is being removed. This change affects airlines and travelers by updating where customs fees apply, helping keep things smooth and fair. No extra costs or delays are expected—just a fresh, official airport lineup!